From Anecdote to Evidence: Why Measuring What We Deploy Changes Everything

Regenerative Health-Biocellular / Orthobiologics Program (GARM)

*Corresponding author:  Robert W. Alexander, MD, FICS, Regenerative Health-Biocellular / Orthobiologics Program (GARM)

Table 1: Proposed standardized terminology for Orthobiologic dose documentation.

Foundational Principle: A treatment cannot be said to have worked if the treatment itself was never defined. Characterizing the biologic deployed is not a research luxury — it is the minimum requirement of responsible clinical practice.

Standards: What Must Be Measured and Why

cSVF characterization parameters

The International Society for Cell and Gene Therapy (ISCT) and analogous bodies have established minimal criteria for mesenchymal stromal cell (MSC) characterization in research settings — surface marker expression, differentiation capacity, and plastic adherence. These criteria are appropriate for laboratory contexts but remain impractical in same-day small clinical procedures. The clinically actionable minimum for cSVF consists of at least three parameters (Table 2).

The Centrifuge as a Measurement Platform

The clinical centrifuge has historically functioned as an output device — it produces a preparation, and that preparation is used. The conceptual shift argued for here is that a purpose-configured centrifuge system, when paired with integrated or adjacent hemocytometric analysis, becomes a measurement platform. This reframing has profound consequences for dose documentation.

The platform under discussion is an all-purpose device capable of processing both adipose tissue (for cSVF) and whole blood (for HD-PRP) within the same clinical encounter. This capability is not a convenience — it is scientifically essential. In biocellular/Orthobiologic procedures, tSVF or cSVF and HD-PRP are typically co-deployed. Characterizing one without the other documents only half the dose data in any given application. (Figure 1) illustrates the integrated five-step documentation workflow.

Figure 1: Integrated point-of-care dose documentation workflow for concurrent cSVF and HD-PRP processing.

This workflow requires no major laboratory infrastructure beyond a small flow cytometer and hemocytometer. The time cost is approximately 8–15 minutes added to the procedure preparation phase. The informational gain is the difference between a characterized biological dose and an uncharacterized biological guess. This approach does not advocate expansion of indications for cSVF; rather, it advocates for documentation of what is actually being delivered to patients undergoing targeted Orthobiologic therapies.

Dose–Response: The Core Scientific Obligation

Every pharmacological and biological therapy approved by regulatory bodies rests on a demonstrated dose–response relationship: as dose increases within a therapeutic range, response changes in a predictable and characterizable way. This relationship is not a regulatory formality. It is the mechanistic signature that distinguishes a therapy from a placebo and an active ingredient from an inert one.

Regenerative cell therapies have, with some notable exceptions, evaded this standard — not because the relationship does not exist, but because dose has not been measured. When every patient receives an unknown dose, dose–response analysis is mathematically impossible regardless of how many patients are enrolled or how carefully outcomes are tracked.

Beyond research and clinical trials: the orthobiologic case

The conventional assumption is that cSVF characterization matters primarily for systemic administration in research protocols or formal clinical trials — intravenous or intrathecal delivery where regulatory scrutiny demands cellular documentation. This assumption deserves direct challenge.

In musculoskeletal and Orthobiologic applications — including tendon/ligament repair, meniscal treatment, intra-articular injection, periosteal delivery, and intramuscular placement — the dose–response question is equally relevant and arguably more tractable. The target tissue is accessible. Outcome measures (VAS pain scores, functional indices, imaging findings) are standardized. The patient population is large and the conditions — osteoarthritis, tendinopathy, ligamentous injury — are among the most prevalent in clinical medicine.

Opportunity Statement: A network of small clinics, each documenting delivered cSVF within the utilized tSVF and HD-PRP at the point of care, and each recording outcomes at standardized intervals, collectively generates a dose-linked outcomes dataset that no single academic medical center could produce in a decade of randomized trials. The unit of evidence production shifts from the trial to each treated encounter.

The potential value extends further. In biocellular/Orthobiologic procedures where concentrations of measured cSVF and HD-PRP are accurately defined and combined, the interaction between the two biologics — whether synergistic, additive, or independent — cannot be assessed unless both doses are characterized. A clinician observing a superior outcome in one patient versus another cannot attribute the difference to preparation technique, processing protocol, or patient biology if the doses administered were never measured.

Transitioning from Anecdote: A Practical Framework

What anecdotal evidence is — and is not

Anecdotal evidence is not without value. The case report and clinical observation have introduced more therapeutic innovations than is commonly credited. The limitation of anecdotal evidence is not its origin but its architecture: it cannot be aggregated, weighted, or falsified. Ten positive case reports and two negative ones cannot be combined into a meaningful signal because the underlying doses, patient characteristics, and outcome definitions are incommensurable.

The transition from anecdote to evidence does not always require a randomized controlled trial. It requires three things: a defined and measured dose, pre-specified outcome measures with a documented baseline, and a record-keeping system that links the two. Each of these is achievable in any clinic that has adopted point-of-care hemocytometry and cSVF documentation.

Minimum viable documentation standard

The following represents a proposed minimum documentation set for any biocellular/Orthobiologic procedure involving cSVF and/or HD-PRP (Table 3).